Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week

By Maxx Chatsko - Updated Apr 15, 2019 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.

What happened

Shares of Axsome Therapeutics (AXSM 0.44%) rose as much as 32.5% today following a 161% gain the day before. From the beginning of the week to 11:40 a.m. EST on Tuesday, the stock has gained 210%, valuing the company at $250 million. Why has Mr. Market plucked this tiny pharma company from obscurity this week?

On Jan. 7, the company reported that its lead drug candidate, AXS-05, hit its primary endpoint in a phase 2 trial evaluating it as a treatment for major depressive disorder (MDD). The results immediately drew comparisons to Sage Therapeutics (SAGE 2.20%), which on Monday announced that its next-generation depression treatment, SAGE-217, successfully wrapped up a phase 3 trial in postpartum depression. The two drugs work differently, but offer a promising glimpse at the future of treatments for depression, which have seen relatively little innovation in the last 15 years. 

As of 11:40 a.m. EST, Axsome Therapeutics stock had settled to a 21.1% gain for the day.

A woman checking her phone and pumping her fist in excitement as cash money falls around her.

Image source: Getty Images.

So what

While many pharma and biopharma companies try to outdo one another by concocting never-before-seen chemistries for new drugs, AXS-05 is a refreshing reminder that there's always low-hanging fruit. The drug candidate is actually two drugs in one: the common cough treatment dextromethorphan (sold under brand names like Vicks DayQuil) and bupropion, a common treatment for depression and helping people to quit smoking (under brand names such as Wellbutrin). Both compounds interact with certain receptors in the central nervous system, while the latter also increases the effectiveness of the former.

Axsome Therapeutics figured that combining the two might create a novel treatment for depression -- and the phase 2 trial results show it might be correct. The well-designed trial included 80 patients, of which 47% taking AXS-05 achieved remission from symptoms in six weeks. The comparison arm of the study didn't use a placebo, but instead gave patients an equivalent amount of bupropion as found in AXS-05. Only 16% of these patients achieved remission.

By comparison, Sage Therapeutics reported that 45% of patients with postpartum depression taking SAGE-217 achieved remission in two weeks, versus 23% taking a placebo. The improvements held up at the six-week follow-up. In late 2019, the drug candidate will complete a phase 3 trial in MDD -- the same depressive disorder treated by the most advanced trial for AXS-05.

Now what

While it's important not to get too carried away drawing comparisons between SAGE-217 (likely headed for marketing approval after completing a phase 3 trial) and AXS-05 (which still needs to start and complete a phase 3 trial), the comparison is pretty impressive for the tiny Axsome. That said, early and mid-stage results for drug candidates treating disorders of the central nervous system are notoriously poor indicators of success in late-stage trials.

Investors should dig around Axsome Therapeutics a bit more before jumping into a position or assuming it will earn a multibillion-dollar market cap like its larger peer Sage Therapeutics. The tiny company appears to be on the right path, but there's still a long way to go.

Check out the latest Sage Therapeutics earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sage Therapeutics, Inc. Stock Quote
Sage Therapeutics, Inc.
SAGE
$32.53 (2.20%) $0.70
Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
AXSM
$31.65 (0.44%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.